LIVECAST Markets Briefs Calendar

Research

News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive Account

Live News EQUITY FLASH L impact Sep 22, 2026, 11:12 AM UTC

Roth Capital starts coverage on Terrestrial Energy with $15 target

00 per-share price target.

SquawkNews Desk

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

IMSR

Related stories

SmartCentres REIT updates financial calendar for quarterly results release and conference call SmartCentres will report Q3 2026 results for the period ended Sept. 30, 2026 on Nov. 4, 2026. Management will host an investor conference call on Nov. 5, 2026 at 2:00 p.m. ET. M impact | EQUITY | Oct 05, 2026, 09:41 PM UTC Capstone Copper to release Q3 2026 results on Oct. 29 Capstone Copper has scheduled its Q3 2026 results release for Oct. 29, 2026, after market close, with an investor conference call to follow. M impact | EQUITY | Oct 05, 2026, 09:40 PM UTC Australia Shares Poised to Open Higher on Wall Street Tech Strength Australian equities are expected to open higher, with ASX 200 futures indicating a 0.3% rise. This follows a record-breaking session on Wall Street, driven by continued momentum in M impact | EQUITY | Oct 05, 2026, 09:36 PM UTC L'Oreal explores unloading chemical liabilities, WSJ reports The cosmetics maker has engaged restructuring advisers to explore options for rising US legal liabilities linked to its use of talc and other chemical ingredients in some of its co M impact | EQUITY | Oct 05, 2026, 09:36 PM UTC Vaxcyte commences offerings of common stock, warrants and notes Vaxcyte Inc. announced the commencement of proposed offerings of common stock, pre-funded warrants, and convertible senior notes, aiming to raise funds for clinical development of M impact | EQUITY | Oct 05, 2026, 09:35 PM UTC Korro Bio: First cohort dosed in Phase 1/2 clinical trial for KRRO-121 Korro Bio has dosed the first cohort in its Phase 1/2 clinical trial (Anchor) for KRRO-121. Dosing in UCD patients is expected to start in H1 2027, with an interim readout in H2 20 M impact | EQUITY | Oct 05, 2026, 09:31 PM UTC

SQUAWK/NEWS

Independent financial newsroom. Editorial expertise and proprietary AI. Paid LiveCast brings live headlines, chart context and priority audio to your trading day. Free research tools remain available.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

News & Research

Open LiveCast
Session Briefs
Macro
Politics
Prediction Markets
News Archive

Markets & Tools

Charts & News
Markets Overview
US Stocks
Market Movers
Economic Calendar
Policy Calendar
AI Market Assistant
News Search
Instrument Directory

Guides

Charts & News Guide
How LiveCast Works
What Is an Audio Squawk?
Why News Moves Markets
News for Traders
How to Trade the News

Plans & API

Plans & Pricing
Institutional API
RSS Feed

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

© 2026 SquawkNews

Privacy Policy Terms of Use

SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.